Activity in a receptor assay or one growth endpoint does not guarantee activity in every physiological system. This older rat study tested that assumption in a lactation model. Primary study
Experimental result
After lactation was suppressed experimentally, the investigators attempted to restore it with several hormonal interventions. Prolactin and growth hormone restarted measured milk-production responses, whereas tested IGF preparations and analogues did not. The analogues included R3-IGF-I, Long-IGF-I, and Long-R3-IGF-I, which were selected to reduce binding-protein interactions. Primary abstract
Our appraisal: a proposed bottleneck was not sufficient
Changing binding-protein affinity addresses one possible constraint on biological availability. If that modification fails to restore an outcome, the result argues against treating that constraint as a complete explanation. It does not show that binding proteins never matter, nor that the analogue lacks activity in every tissue.
The model also involves experimentally suppressing more than one hormonal input. Replacing one downstream factor may not restore the coordinated processes needed for a complex organ function. A pathway diagram with a single arrow from growth hormone to IGF cannot substitute for direct testing of the whole physiological outcome.
Molecular names require care here. R3-IGF-I, Long-IGF-I, and Long-R3-IGF-I are distinct constructs, not interchangeable spellings. Their individual findings should remain identifiable when the report is summarized.
The accessible abstract is truncated, so detailed mechanistic and safety conclusions require the complete paper. Nonetheless, its reported negative functional result should not be omitted merely because related growth effects have been observed elsewhere. This study is a useful counterexample to universal “more bioactive means better at every function” reasoning. It does not establish a human lactation intervention or support self-administration of an IGF analogue.
Frequently asked questions
Was this a human study?
No; it used rats.
Did all active growth-related peptides restart lactation?
No.
Was Long-R3-IGF-I among the tested analogues?
Yes.
Are all three analogue names equivalent?
No.
Does this imply the analogues are inactive everywhere?
No.
Was the accessible abstract complete?
It was explicitly truncated.
What is the central interpretation lesson?
A molecular activity cannot be assumed to reproduce a complex organ-level function.